Need considerable resources material and human.

Similar documents
5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

What s a Transplant? What s not?

Reduced-intensity Conditioning Transplantation

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Lynn B. Bonifacio, MD, FPCP, DPSHBT National Kidney and Transplant Institute Philippines

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Mobilization & Pre-Transplant Conditioning Regimens

Pediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center

ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD

Stem Cell Transplantation for Severe Aplastic Anemia

THE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update

An Introduction to Bone Marrow Transplant

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT

An Overview of Blood and Marrow Transplantation

Dr.PSRK.Sastry MD, ECMO

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt

Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center

AIH, Marseille 30/09/06

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust

Bone Marrow Transplantation and the Potential Role of Iomab-B

Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA. Binod Dhakal MD, MS Jeanie Esselmann, RN

UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia

Stem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT

Hematopoietic Cell Transplantation for Myelofibrosis. Outline

Stem cell transplantation. Dr Mohammed Karodia NHLS & UP

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

Back to the Future: The Resurgence of Bone Marrow??

Hematopoietic stem cell mobilization and collection. Koen Theunissen Hematologie Jessa Ziekenhuis Hasselt Limburgs Oncologisch Centrum

Hematopoietic Stem Cells

Bor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

Haploidentical Transplantation today: and the alternatives

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD

Hematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia

Blood and Marrow Transplant (BMT) for Sickle Cell Disease

Post Transplant Management for Sickle Cell. Title

WAA/SFH Joint Congress

4nd Patient and Family Day

BMTCN Review Course Basic Concepts and Indications for Transplantation. David Rice, PhD, RN, NP

Comparing outcome between Belgian haematopoietic stem cell transplant centres

A CLINICAL STUDY OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 112 PATIENTS WITH LEUKEMIA AND OTHER MALIGNANT DISEASES

Pediatric Hematopoietic Stem Cell Transplantation. Meng Yao Lu/ Kai Hsin Lin Department of Pediatrics National Taiwan University Hospital

Induction Therapy & Stem Cell Transplantation for Myeloma

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.

London, 27 October 2005 Product Name: Busilvex Procedure no.: EMEA/H/C/472/II/0004 SCIENTIFIC DISCUSSION

Samples Available for Recipient Only. Samples Available for Recipient and Donor

THE LEUKEMIAS. Etiology:

Leukemia. There are different types of leukemia and several treatment options for each type.

Management of Multiple Myeloma: The Changing Paradigm

Late effects after HSCT

Late effects, health status and quality of life after hemopoietic stem cell

Hematopoietic Stem Cell Transplantation for Fanconi Anemia

Samples Available for Recipient and Donor

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

Haploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy

Where in the TED Does HCT Stuff Go?

Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience

Long-Term Outcomes After Hematopoietic Cell Transplantation

Instructions for Pre-Transplant Essential Data (Pre-TED) Form (Version 2) TABLE OF CONTENTS

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.

EBMT Complications and Quality of Life Working Party Educational Course

Latest results of sibling HSCT in acquired AA. Jakob R Passweg

Hematopoetic Stem Cell Therapies in TURKIYE

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

Umbilical Cord Blood Transplantation

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

Mobilization. Mobilization & Pre-Transplant Conditioning Regimens Stephanie Fellingham, RN, BSN, OCN. Transplant Process.

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS

Cost issues. BLOOD AND CANCER SECRETS May, 2014 Vol. 2, N1

Lung Injury after HCT

Non-Myeloablative Transplantation

RIC in Allogeneic Stem Cell Transplantation

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017

options in Myeloablative HSCT

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

CIBMTR Center Number: CIBMTR Recipient ID: Today s Date: Date of HSCT for which this form is being completed:

ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES

Review of Aplastic Anemia Guidelines. Seiji Kojima MD. PhD.

Corporate Medical Policy

Le infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy

Extramedullary Relapse of the AML Transformed from MDS Following Auto-HSCT: A Case Report

Bone Marrow Transplantation in Neurological Disease

Transcription:

TRAN VAN BINH

INTRODUCTION Hematopoietic Stem cell transplantation: the best way to manage Malignancies and non Malignant blood disorders. Need considerable resources material and human. In developping countries: great challenges to select patients by many problems both by indications and material possibilities. Our experiences from VIETNAM: since 1996: 152 cases performed.

COUNTRY PROFILE VIETNAM: the small country of the Indo-China Peninsula * Population: 85 millions (3 rd most populous after Indonesia and Philippine) * 58.9%< 25 years of age, * Population density 259 /km 2, Percapita income 1.052 USD /year, * 29.6% live in city

COUNTRY PROFILE North VietNam: 6 Transplantation Centers: 108 th Military Institute (8 cases); Pediatric Institute (6 cases); Police Hospital (1 case); National Blood Transfusion and Hematology Institute (35 cas) Middle VietNam: Hue Central Hospital (5 cases) South VietNam: Blood Transfusion and Hematology Hospital HoChiMinh City (98 cases)

THE 6 BMT CENTERS OF VIETNAM 4 centers 1 center 1 center

THE TRANSPLANT UNIT 10 FIRST TRANSPLANTATIONS: Clean room: isolated, double door, furnitures decontaminated by UV and pulverized chemical, water filtrated. Patients sterelized: hair cut, antiseptic baths, decontaminated GI tract by non absorbable antibiotics, well cooked foods. Physicians: Wash hand From 2005: Positive pressure ventilation, HEPA 6 well trained nurses permanent take care of patients run by 6 physicians for adults, 2 for pediatric patients supported by all others departments of the hospital

CHOICE OF PROTOCOLS MOBILISATION: For Autologous: Stem cell extracted by cytapheresis after Cyclophosphamide (1-2 g/m 2 on D1, D2); G-CSF (10 µg/kg); cell dose MNC > 3 x10 8 /kg or CD34+ > 2 x10 6 /kg. Autologous for CML: Mobilisation by mini ACE (Daunorubicin 50 mg/m 2 x 5 days; AraC 3 days; G-CSF 10mg/kg x 7 days) CONDITIONING REGIMENS: (Allogeneic) TBI not available. Must use conditioning by only Chemotherapy: Bu/Cy Protocol (AML, ALL, Thalassemia) Busulfan 4 mg/kg/day x 4 days; Cyclophosphamide 60mg/kg/day x 2 days ; G-CSF 5µg/kg from the cell nadir

Odansetron, Dexamethasone (for vomiting) Cyclophosphamide, short course of methotrexate for GVHD BEAC for NHL (BCNU, Etoposide, AraC, Cycophosphamide) ATG, Cyclosporine for SAA All patients tolerated well, Engrafments between acceptable limits MELPHALAN high dose (180 mg), Storage bone marrow and stem cell at 4 o C (<72h) (at the begining, cryopreservation not available) for some acute leukemia (good results, long survival)

SUPPORTING MANAGEMENT Isolation, sterile nursing, clean room (before 2005), laminar air flow Blood and blood components transfusion (irradiated) Preventive antibiotherapy, appropriate infection diagnosis, empirical antibiotherapy Diagnosis and management of complications: GVHD, VOD Tight cooperation between clinicians and lab

SOME RESULTS OF HOCHIMINH CENTER Number of cases : 98 Transplantation procedures ALLO HSCT BMT CORD BLOOD PBSCT AUTO PBSCT Without cryopreservation With cryopreservation No of cases 45 4 10 31 53 24 29 Rate % 46 4 10 32 54 24.5 29.5

DISEASES TREATED No of cases Rate % AML 63 65 ALL 6 6.2 CML 17 17.5 NHL 3 3 Thalassemia 7 7.3 A. Anemia 2 2 Median Ages: 28 (4-50)

* Blood Transfusion and Hematology Hospital treat > 500 cases of leukemia and other non malignant disease / year * Indication for Transplants > 100 * BMT done 10-20 ( year : < 10% of need ) * Many difficulties to be overcome

I/- THE COST OF THE PROCEDURE * Effort to reduce the cost of the operation (Intensive conditionning, aggressive care) (lowest in Asia) the majority of the population (>90%) cannot afford the cost (price much less than Western countries): Allo BMT: 20.000 USD (15.000 without complication; serious complications: 45.000 50.000) In Children: 15.000USD (medications,consumable materials; imported ) covered partially by National Medical insurance

Rich patients: BMT done abroad (Singapore, US) Not confident in our limited expriences, Unavailabilty of full range of medications (in cases of complication: GVHD, VOD ): Blood products, Antibiotics, Antifungal ) Difficulty to make follow up : some patients live far of the hospital 2/-IMPROVE THE OVERALL LEVEL OF MEDICAL CARE OF THE COUNTRY: Great problems about improvement of level of Medical care: - Low Budget for Hospital Modernization - Salary of medical doctor still low exodus of qualified specialist in other countries The remaining private practice reducing time for study and research; 400 hematologists /85 millions. Very few in transplantation field

Hematologists : Lack of awareness of Indication and efficacity of Transplantation procedures. Majority of patients refered to us at late stage after heavy treatment and toxicity limiting possibility of useful interventions 3/- DIFFICULTY OF FINDING APPROPRIATE DONORS: Allogeneneic unrelated unavailable by lack of National Bone Marrow Registry Perfect mathched related donors : more and more difficult to find ( sibbling ) : Vietnamese family size shrink by National Birth control program Autologous, cord blood as alternative sources

4/- PATIENT EVALUATION PRIOR TO TRANSPLANT : All transplantation candidates must have preevaluation in order to have good outcome : -Autologous patients : no active disease in the bone marrow, adequate collection of PBSC from peripheral blood - Allogeneneic patients : sibbling donor matched HLA, age, CMV - Patient Performance status, age, disease stage ( Indication )

Extensive evaluation by the transplant physician : -Guide the informed consent process -Psychiatric social behavior - Physical examination, evaluation of all organ functions : oral cavity, lung, liver, heart, kidney, central nervous system. Karnosky score, infectious disease story : viral ( CMV, HBV, HCV, HIV, Fungi ), previous chemotherapy, radiation, transfusion history, - Patient must satisfy criteria according to specific protocol - Possibibity of follow up ( live < 200km ) These strict criterias eliminate some potential patients

* Waiting New technics less expensive, less risky procedures of BMT * Immediate planning, try to sustain our activity, enlarge it by introducing new technics like Non myeloablative ( treat more older patients > 50 yo ), aploidentical ( donors in the same familily ) * Need to develop more transplants centers, introduce BMT possibilities to more provinces by transfert of technology - Try to work with medical insurance to cover more, to lower the participation of patient and family in the cost - Challenges should be solved not only by medical profession but by the entire vietnamese society

FROM NOTHING TO EVERYTHING AND BEYOND

OUR MOST PRECIOUS RESOURCE THE TRANSPLANTATION TEAM

Clean room, sterile nursing

THE TRANSPLANTATION UNIT STERILE NURSING, HEPA FILTER

BLOOD PRODUCTS GOOD TRANSFUSION PRACTICE

IRRADIATION OF BLOOD PRODUCTS

CYTAPHERESIS PERIPHERAL BLOOD STEM CELL HARVEST

CORD BLOOD BANKING PROCESSING OF STEM CELL AND CORD BLOOD

CRYOPRESERVATION BIOARCHIVE SYSTEM

LABORATORY SUPPORT

FLOW CYTOMETRY

MOLECULAR, CYTOGENETIC

THE BLOOD TRANSFUSION AND HEMATOLOGY HOSPITAL OF HO CHI MINH CITY